Panacea

Two-person startup selling fixed-price, AI-assisted FDA regulatory filing services.

Panacea has a pricing angle and human credibility but no named customers yet, in a category two other funded startups already occupy.

Panacea handles FDA paperwork and approvals on a flat-fee basis instead of charging by the hour, which traditional consulting firms and contract research organizations like IQVIA and Parexel have not done. The company's advantage rests on hiring former FDA staff who are willing to put their names and reputations behind the work, making clients trust the output more. However, this advantage is fragile: larger consulting firms and AI companies are now copying the same model, and better artificial intelligence could eventually write much of the regulatory documents automatically, which would shrink what humans need to do and what Panacea can charge. The one thing that matters most is whether Panacea can keep hiring and keeping those ex-FDA people as real employees who own part of the company, not just freelancers, while Deloitte, EY, and other big rivals fish from the same small talent pool.

• 2 employees as of Jul 2026 (Jul 22, 2026)
• Rhizome AI prices at $4,000 per seat per year (Jun 24, 2026)
• Certara claims ~30% drafting time savings from AI patent (Mar 20, 2026)

• No disclosed revenue, ARR, or named customers as of July 2026. Severity: high
• Only two employees with no confirmed funding beyond standard YC investment. Severity: high
• Ex-FDA talent pool is small and shared with Big-4, Certara, and better-funded YC peers. Severity: high
• YC Fall 2026 RFS could bring a wave of new AI-compliance entrants within months. Severity: medium
• No proprietary data or integration lock-in; moat depends entirely on hired personnel. Severity: medium

Is Panacea profitable in 2026?

No. Panacea is a 2-employee, San Francisco based YC P2026 startup with no disclosed revenue, ARR, or named enterprise customers as of July 2026. Its only confirmed funding is YC's standard batch investment, with no independent venture round reported.

Could AI replace Panacea's FDA regulatory consulting service?

Not fully. Panacea's model pairs AI drafting with named ex-FDA consultants who bear legal and reputational liability for filings, something a pure AI tool cannot offer clients. This human-accountability layer is a real seal, but it protects the whole category, not Panacea specifically, as of 2026.

Who are Panacea's biggest competitors?

Direct YC peers Ritivel (AI drafting agents for CTDs, CSRs, INDs, BLAs, as of June 2026) and Rhizome AI (44 million document regulatory dataset, priced around $4,000 per seat per year, June 2026), plus incumbent Certara and Big-4 firms like Deloitte and Accenture.

Who owns Panacea?

Panacea is privately held and backed by Y Combinator (P2026 batch). It was founded by CEO Haris Javed-Akhtar (MD) and CTO Yaman (MS in AI), both previously at health-plan AI company Anterior, per YC's company page as of 2026.

Does Panacea have any paying customers?

No named customers have been confirmed as of July 2026. Panacea's website features only an unnamed client testimonial and a vendor-claimed 60% faster speed statistic, with no independently verified case studies or logos.

What makes Panacea different from traditional FDA regulatory consultants?

Panacea charges fixed, milestone-based outcome pricing instead of hourly billing, arguing hourly-billing consultants are structurally disincentivized to use AI to work faster, according to its own site and YC company page as of 2026.

• 2026-07-26YC issues Fall 2026 Request for Startups calling for AI-native compliance infrastructure entrants
• 2026-07-22YC directory lists Panacea active with 2 employees in San Francisco
• 2026-06-24Peer Rhizome AI covered with 44 million document regulatory dataset, ~$4,000 per seat per year
• 2026-06-22Peer Ritivel listed in YC Biotechnology directory as AI drafting agent for CTDs, CSRs, INDs, BLAs
• 2026-05-18YC Launch post for Panacea published, implying public launch around March-April 2026
• 2026-05-03FDA's internal AI tool Elsa reported integrated into scientific review and inspection targeting
• 2026-03-20Certara's 2025 AI drafting patent reported, claimed ~30% time savings
• 2024-06-10Founders' prior company Anterior raises $20 million Series A

• Healthcare Services Startups funded by Y Combinator (YC) 2026 (Jul 22, 2026)
• Panacea: AI-Native FDA Regulatory Services
• Launch YC: Panacea: AI-Native FDA Regulatory Services (May 18, 2026)
• Your AI-native FDA regulatory team
• Complete Analysis
• Biotechnology Startups funded by Y Combinator (YC) 2026 (Jun 22, 2026)
• Claude's Corner: Rhizome AI, The FDA Whisperer for Biotech (Jun 24, 2026)
• What is Competitive Landscape of Certara Company? (Mar 20, 2026)
• What the FDA Actually Says About AI in Medical Devices (May 3, 2026)
• How to Build AI-Native Compliance Infrastructure (Jul 26, 2026)
• Anterior Secures $20 Million Series A (Jun 10, 2024)
• Valuation, Funding Rounds & Stock Price (Jul 13, 2025)